source
- FDA approves Zenbexus for multiple myeloma as NSAI looks to sell MDR notified body unitThe U.S. Food and Drug Administration has granted approval for Zenbexus to be used in the treatment of multiple myeloma, marking a new therapeutic option for patients with this blood cancer. The a…
- EyePoint’s Phase 3 trial of duravyu fails to outperform aflibercept, shares plunge 70%EyePoint announced that its Phase 3 Lugano trial of the investigational tyrosine kinase inhibitor duravyu did not meet the primary efficacy endpoint when compared with the standard‑of‑care anti‑VEG…